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Abstract: Antibiotic poly-resistance (multidrug-, extreme-, and pan-drug resistance) is controlled
by adaptive evolution. Darwinian and Lamarckian interpretations of resistance evolution are
discussed. Arguments for, and against, pessimistic forecasts on a fatal “post-antibiotic era” are
evaluated. In commensal niches, the appearance of a new antibiotic resistance often reduces fitness,
but compensatory mutations may counteract this tendency. The appearance of new antibiotic resistance
is frequently accompanied by a collateral sensitivity to other resistances. Organisms with an expanding
open pan-genome, such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae,
can withstand an increased number of resistances by exploiting their evolutionary plasticity and
disseminating clonally or poly-clonally. Multidrug-resistant pathogen clones can become predominant
under antibiotic stress conditions but, under the influence of negative frequency-dependent selection,
are prevented from rising to dominance in a population in a commensal niche. Antimicrobial peptides
have a great potential to combat multidrug resistance, since antibiotic-resistant bacteria have shown a
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high frequency of collateral sensitivity to antimicrobial peptides. In addition, the mobility patterns of
antibiotic resistance, and antimicrobial peptide resistance, genes are completely different. The integron
trade in commensal niches is fortunately limited by the species-specificity of resistance genes. Hence,
we theorize that the suggested post-antibiotic era has not yet come, and indeed might never come.
Keywords: MDR; intrinsic/acquired resistance; collateral sensitivity; negative frequency-dependent
selection; experimental evolution; pangenome; global dissemination; mobility patterns of resistance
genes; adaptive evolution
1. Introduction
The rapid and ongoing spread of antibiotic resistance poses a serious threat to global public
health [1]. Considering the complexity of the sophisticated resistance mechanisms [2,3], recruiting
cooperating scientists with different backgrounds seems reasonable and necessary. This review is
addressed to committed scientists, biologists, geneticists, and evolutionary biologists who may be
attracted by fundamental, rather than applied, research perspectives. We focused on selected aspects.
One is the danger posed by globally spreading monoclonal pathogens (Acinetobacter baumannii [4–6],
Pseudomonas aeruginosa [7–9]), with an expanding open pangenome, being aware that they are not the
only ones displaying a threat.
Antibiotic resistance was discovered in 1940 [10]. The selective pressure of antimicrobials is
favorable for resistant clones to survive and spread [11]. The emergence of antibiotic multiresistance
(MDR) in pathogenic bacteria has become alarming in the last decades [12]. MDR appeared not only in
human clinical pathogens [13–16] but also in zoonic bacteria [17,18], veterinary pathogens [19–26], and in
plant pathogens [27–32]. Although application technologies are improving for plant pathogens [33],
the trend has been that the use of antibiotics as plant medicines has gradually been restricted [34,
35]. A precondition for elaborating appropriate therapies is having a better understanding of
antibiotic resistance mechanisms [36] in Gram-negative [13,16,37] and Gram-positive [38–41] pathogens.
New “bugs” are continuously appearing, and new antibiotics are needed. Conly and Johnson asked in
2005 “Where are the new antibiotics?” [42]. The tantalizing answer came 11 years later: Antibiotics are
“right under our nose!” [43]. Unfortunately, they still have not made it to market [44], at least not in the
required number [45,46].
2. Multidrug Resistance: Updated Terms and Definitions
The genomes of different bacterium species harbor silent genes that code for resistance, but in the
absence of antibiotics it is not manifested. Consequently, a large pool of potential of antibiotic resistance
genes is hidden in various niches. The term antibiotic resistome covers the collection of all antibiotic
resistance genes, including those associated with both pathogenic and non-pathogenic bacteria, but not
ones which produce antibiotics [47]. Pál and his associates provided a comprehensive characterization
of resistance genes, mobile genetic elements (MGEs), and bacterial taxonomic compositions for 864
metagenomes from humans (n = 350), animals (n = 145), and external environments (n = 369), all deeply
sequenced using Illumina technology. They concluded that antibiotic-polluted environments are
probably under-estimated transmission routes, and indeed reservoirs for antibiotic resistance [48].
2.1. Antibiotic Resistance as a Phenotype
The resistance genotype [49–51] determines the resistance phenotype. Take the evolutionary
history of Mycobacterium tuberculosis resistance to second-line anti-tuberculous as a scholarly medical
genetic example to illustrate the simple Mendelian genotype–phenotype relations [52–55].
Genetic suppression of the cellular autolytic system of pneumococci causes simultaneous resistance
to penicillin, D-cycloserine, and phosphonomycin [56], providing an example of the iso-allelic
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inheritance phenotype [57,58]. Physiological suppression is similar [56], providing an example of the
old genetic term, phenocopy [59,60]. The clarification of genotypic/phenotypic relations is a prelude to
the application of clinical metagenomics [61].
2.2. The Location and Harboring of the Resistance Genes
The resistance gene is a peptide-coding open reading frame, genetically regulated as structure gene
of an operon. The higher level of organization is the antibiotics resistance cassette [62–64]. The respective
resistance gene(s) could be localized either on the chromosome [51], or in a plasmid [65–69], either as
non-conjugative [62], conjugative [70,71], or in an episome [72].
2.3. Insertion and Excision
The resistance gene as an integron component [71,73] can be harbored by a mobile genetic element
capable of inserting into, and excising from, another DNA molecule like a plasmid. This has been
reviewed by several authors [74–79].
2.4. Homolog Recombination
Some mobile elements are capable of recombining with the bacterial chromosome, allowing
transfer of large segments, as shown with vancomycin and penicillin resistance transfer, at least in
Gram-positive (Enterococcus) pathogens [80,81]. Horizontal gene transfer (HGT) could happen even
between the different bacteria taxa [82,83].
2.5. Intrinsic Resistance (IR)
IR is the phenotypic expression of a resistance gene originally present, resulting in structural
and functional changes of the original gene product [84,85]. This can be either a decomposing
enzyme [86–88], or the target site of the drug [89,90]. The most efficient resistance mechanisms are the
multidrug efflux pumps [91–94].
When resistance to antimicrobial compound is a phenotypic expression of a resistance-encoding
gene coming from outside via horizontal gene transfer HGT [95–100], it is called “acquired”
resistance [85,101]. The gene from outside had been harbored by a plasmid and was taken up
from the environment, such as from soil [102,103] or the gastrointestinal [83,99] microbiota community.
Expansion of KPC-producing Klebsiella pneumoniae with various mgrB mutations giving rise to colistin
resistance [104], and the bla (VIM-1) metallo-beta-lactamase producing. E. coli was published to
spreading over in a university hospital in Greece [105]. These are examples of concerted activities of
mobile genetic elements, including insertion sequences, transposons, and gene cassettes/integrons,
and has been summarized by Partridge et al. [79]. Horizontal gene transfer (HGT) could even happen
between different bacteria taxa [82,83].
The novel phenomenon called distributive conjugal gene transfer (DCT) was recently discovered
in mycobacteria. DCT involves the transfer of chromosomal DNA between mycobacteria and,
most significantly, generates trans-conjugants with mosaic genomes of the parental strains [106].
2.6. Definitions of Antibiotic Polyresistant Strains
Antibiotic resistances [2,3] are classified as follows: multidrug resistant (MDR) is not susceptible to
at least one representative from each of three categories of selected antimicrobial compound families [3].
Extreme drug-resistant (XDR) is not susceptible to at least a single representative of all but very few
categories of antimicrobial compound families. Pan-drug resistant (PDR) is not susceptible to any of
the tested representatives of all known antimicrobial compound families [3].
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2.7. The Updated List of the “ESKAPE” Polyresistant Pathogenic Bacterium Species
In 2006, the Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society
of America (IDSA) prepared a review that highlighted frequently resistant pathogens to licensed
antimicrobials [36], characterized by high antibiotic resistance, and extremely versatile MDR phenotypes
which are responsible for many nosocomial infections [36]. As for their clinical significance [107],
the updated the list of six ESKAPE Pathogen Bacterium Species appeared in 2008 [18]. The six
letters are the initials of the genera of these bacteria: Enterococcus faecium, Staphylococcus aureus,
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. [108–112].
There is “NO DRUG” against them and “NO ESKAPE” from them [109]. They include causative
pathogens of nosocomial diseases, such as ventilator-associated pneumonia [113,114], infections
in burn wounds [115], and pathogens which “escape” from antimicrobial agents [109,116,117].
Immune-compromised patients are most exposed to ESKAPE pathogens causing bacteremia [118].
The ESKAPE list has recently been updated by the World Health Organization (WHO) [119].
It includes the carbapenem-resistant Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, carbapenem-resistant and third-generation cephalosporin-resistant Enterobacteriaceae,
clarithromycin-resistant Helicobacter pylori, fluoroquinolone resistant Campylobacter spp., Neisseria
gonorrhea, and Salmonella typhi as community-acquired infection-causing pathogens. The highest-ranked
Gram-positive members are vancomycin-resistant Enterococcus fecalis and Ent. faecium, as well as
the methicillin-resistant (MRSA) S. aureus [119]. The resistance mechanisms used by the ESCAPE
pathogens were recently reviewed [120].
Some other dangerous Gram-negatives such as Escherichia coli, Francisella tularensis, and Gram-
positives Mycoplasma bovis and Bacillus anthracis may be considered as putative “ESKAPE Club-Members”
in the future. We discuss this option in Supplementary Material 1.
3. Resistance Problems Related to Gram-Negative Pathogens
The logical chain of events leading to multidrug resistance in Gram-negative pathogens is
illustrated in Figure 1. (LEFT).
3.1. B-Lactams vs. ESBL Resistance in Enterobacteriaceae and Klebsiella pneumoniae
The β-lactams were introduced to overcome penicillin resistance by preventing re-assembly of
peptidoglycan bonds, which eventually leads to cell lysis [121,122]. Extended-Spectrum B-Lactamase
(ESBL) producing Enterobacteriaceae and K. pneumoniae pathogens are resistant to β-lactam-based
antibiotics. The emergence of, and challenges by, ESBL-producing Enterobacteriaceae has been
reviewed over the last three decades [123–126]. Pitout suggested that in vitro resistance to ceftazidime,
and/or aztreonam, should be used as phenotypic markers of ESBL [127]. In Gram-negative bacteria,
the β-lactamase production is frequently associated with reduced permeability of the outer membrane
efflux [128].
Biochemistry has increased the number of β-lactamase enzymes with enlarged substrate
specificities [129]. The substrate range includes cephalosporins (cefotaxime, ceftriaxone [130–132]),
monobactam aztreonam [133–135], amino-penicillin combinations [136], lactamase inhibitor ampicillin-
sulbactam [137–140], ureido-penicillins [141,142] including piperacillin/tazobactam [143–146],
temocillin [147], piperacillin/tazobactam [148], and ceftolozane-tazobactam [149]. Furthermore,
the appearance of new enzymes is not associated with the loss of ability to hydrolyze the earlier
lactams, such as ampicillin [36]. In addition, the prevalence of ESBL production among E. coli and
Klebsiella species is variable [13]. ESBL can be considered as first strike back from the Gram-negative
pathogens or as the first “Wedge” from Nature.
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3.2. Carbapenems: A Strong Antibiotic (“High Card”) to Beat the “Wedge” ESBL
To overcome ESBL problems, a new beta-lactam class of antibiotics, the carbapenems [150,151],
was developed [152], including blood and respiratory isolates of P. aeruginosa [153]. As Breilh and
his associates summarized, they act either as “slow substrate” β-lactamase inhibitors or by binding
to penicillin-binding proteins [154]. This “value-added feature” of inhibiting β-lactamases serves
as a major rationale for the expansion of this class of β-lactams [155]. Carbapenem antibiotics,
including imipenem, are Gram-negative cell-wall synthesis interrupting molecules, which bind to
penicillin-binding proteins [156]. Cilastatin is a human enzyme, dehydropeptidase, in the kidney
that inhibits imipenem degradation and meropenem [156], as well as ertapenem [157]. Each one
alone, or in combination, had been a putative last line of defense against multidrug-resistant
Gram-negative organisms.
3.3. Carbapenem Resistance: The Second Strike Back from the Gram-Negative Pathogens
(“Wedge” from Nature)
Since 2006, the number of carbapenem-resistant Enterobacteriaceae (CRE) has significantly
increased [158–160]. A novel, epidemic, serine class-A type enzyme (KPC) is behind carbapenem
resistance. It is encoded by the Bla (Oxa) gene family [161–165]. KPC exhibits powerful activity against
all types of Beta-lactam molecules [166–168].
3.4. NDM1
A novel type of plasmid-encoding carbapenem-resistant metallo-β-lactamasecarbapenemase
NDM 1 [169] was identified in 2008 in two Enterobacteriaceae isolates, both recovered from a
Swedish patient transferred from India [170]. The emergence of NDM-expressing enterobacteria [171]
and Klebsiella [172,173] was then reported from all continents, but it recently reappeared in Italy
(Toscana, Z. Koncz, personal communication). There are publications on NDM 1 expressing
Acinetobacter [174], Pseudomonas [175], and only one E. coli publication [105]. It has never been
found in Gram-positive bacteria. Klebsiella pneumoniae, Acinetobacter, and Pseudomonas are spread
by clonal dissemination [176], while E. coli and other Enterobacteriaceae spread through polyclonal
dissemination [177]. Many carbapenem-resistance genes localized on mobile genetic elements have
been previously reviewed [178–184].
3.5. “Dropped and Rediscovered” Colistin, as a Large Spectral Antibiotic (a “Trump Card”)
The cationic lipopeptides polymyxin B, E, and colistin [185] disrupt outer membranes (OMs) and
have been used since 1959 for treating infections caused by Gram-negative MDR pathogens. However,
nephrotoxic side effects were discovered [186]. Since the appearance of several new infections caused
by MDR Gram-negative organisms [187,188], and intensive searches of old antibiotic options, colistin
was rediscovered and considered to be a potential trump card [189–194].
3.6. Colistin Resistance: The Third Unexpected Attack (“Wedge”) from Nature
The first colistin-resistant mutant was reported in 1981 [195]. The appearance of colistin resistance,
especially plasmid-mediated transferable ones [196–201], questioned whether the polymyxins should
be considered as the last “life-savers” [202]. Colistin resistance is a consequence of post-translational
modification, or loss, of the lipopolysaccharide (LPS) molecules [203]. The first colistin-resistant
mutant was reported in 1981. The appearance of colistin resistance, especially the plasmid-mediated
transferable ones, questioned whether the polymyxins were still be considered as the last “life-savers”.
The mechanisms of acquired and intrinsic resistance of polymyxin in different bacteria have recently
been reviewed by many authors [204–209]. The genetic factors behind colistin resistance are mcr
genes [198,210,211]. Colistin resistance has been evolving under clinical conditions [212,213] in
A. baumannii [214–216], P. aeruginosa [217], K. pneumoniae [218,219], and Enterobacter cloacae [220].
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The evolution of colistin resistance was more than a one step process, requiring mutation in at least
five independent loci synergistically, creating the resistant phenotype [211,212,221,222].
3.7. Efforts to Overcome MDR Problems in Gram-Negative Pathogens in the Absence of Omnipotent
(“Jolly Joker”) Antibiotics
The potentiation of β-lactam antibiotics and β-lactam with β-lactamase inhibitor combinations
was effective when used against MDR and XDR P. aeruginosa, using non-ribosomal tobramycin–
cyclam conjugates [223,224]. A detailed evaluation of publications reviewing arguments
for and against combining colistin and carbapenems controlling infections caused by
carbapenem-resistant Enterobacteriaceae (CRE), K. pneumoniae carbapenemase (KPC)-producing
bacteria, and carbapenem-resistant A. baumannii (CRAB), based on randomized controlled trials in
which treatment with colistin was in combination with meropenem or rifampin, showed it did not
work as expected. This demonstrates that the use of some polymyxin has always been necessary when
either CRAB, CRE, or CRPA harboring metallo-beta-lactamases are at stake [225]. The combination
strategy is especially useful when the applictiin design is syncronized with the results by obtained
the recently published cassette assay [226] (aiming efficiently quantifying the outer membrane (OM)
permeability of multiple β-lactams in carbapenem and colistin-resistant Klebsiella. pneumoniae) and
enabling to rationally optimize the use of the dose of synergistic β-lactam antibiotics, [226].
4. Resistance Problems Related to Gram-Positive Pathogens
The logical chain of events leading to multidrug resistance in Gram-positive pathogens is illustrated
in Figure 1. (RIGHT).
Streptococcus and Enterococcus species are intrinsically resistant to beta-lactams [227]. They use
beta-lactamases and/or just [228] penicillin-binding polypeptides [229]. This has been reviewed by
Funda and his associates [230].
4.1. Methicillin-Resistant Staphylococcus aureus (MRSA)
Since the early sixties [231], multiresistant pathogen strains [232,233], including those resistant to
vancomycin, have appeared [234]. MRSA is the causative agent in many diseases worldwide [235].
This includes nosocomial infections like pneumonia [236], spondylodiscitis [237], colonization of
burns and wounds [238,239], endocarditis [240], and renal problems [241], all of which have greatly
increased hospital death tolls [242]. Methicillin-resistant S. aureus (MRSA), and S. epidermis isolates,
from companion animals have been reviewed [243,244]. Previously, the clinical use of vancomycin,
synergistically combined with antibiotics, was suggested against poly-resistant clinical isolates [245].
However, vancomycin and daptomycin resistance have developed in the same patient within
hours [246].
4.1.1. The Molecular Basis of MRSA
Extreme methicillin resistance is polygenicly inherited [247]. The responsible chromosomal
DNA segment of ~50 kb, named mec, consists of the open-reading frame mecA coding for the
penicillin-binding protein 2a (PBP 2a), linked to the regulatory genes mecI and mecR1, which control
mecA expression. A variable number of resistance determinants are also included [248]. Strains
lacking mecA may show low-level methicillin resistance, due to modifications in native PBPs, or the
expression of beta-lactamase [249]. However, there is only one publication on methicillin decomposing
an enzyme [250], which has not been confirmed.
4.1.2. The Accelerated Evolution of MRSA
MRSA evolution started when the mecA was acquired, probably when the penicillinase-resistant
oxazolidines were introduced [251]. The genetic profile, antibiotic resistance and bacteriophage profiles,
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and the pulse-field patterns of contemporary epidemic MRSA clones were very similar to those of the
early methicillin-sensitive (MSSA) isolates [252].
The evolutionary history of MRSA was reviewed by Antignac and Tomasz [253]. The donor S. sciuri
strain has a mecA-homolog gene, capbpD, coding for the penicillin-binding protein PBP 4. The mecA
gene is harbored by a SCCmec element and was horizontally transferred to an originally sensitive
(MSSA) strain of S. aureus [253]. Since this discovery, an international working group (IWG-SCC) has
been concentrating on the classification of “Staphylococcal Cassette Chromosome Elements” [254,255].
Another team (Cepheid Healthcare-Associated Infection (HAI) Consortium) has continuously been
addressing the changing epidemiology of MRSA isolates, with the recognition of both “empty cassette”
strains, where mecA is lost from the SCCmec cassette, and the emergence of SCCmec variants [256].
The first MRSA isolates, followed by applied Bayesian phylogenetic reconstruction, provided an option
for reconstructing further details of the evolutionary history of the archetypal MRSA [257]. Harkins and
his associates assumed the approximate date at which the earliest MRSA lineage harboring the SCCmec
appeared was about the mid-1940s, the era of methicillin [257]. The research field of staphylococcal cell
wall structure has gradually gained in its significance [258]. Streptococcus pneumoniae has a complex
cell wall that plays a key role in contributing to pneumococcal resistance to lysozymes [259].
4.2. Enterococci: The Gram-Positive “Vanguards” of the “MDR Movement”
Enterococcus species (Ent. faecium, Ent. faecalis, Ent. gallinarum, and Ent. cecorum; for taxonomy,
see Wikipedia) are facultative anaerobes that exist as commensals in the gastrointestinal tract of a
variety of organisms, including humans [260]. Six penicillin-binding proteins (PBPs) were identified in
the first clinical isolates [261]. From samples studied, Ent. faecium was found to be the most resistant to,
and showed the lowest affinities for, penicillin, while Ent. bovis was the most penicillin-sensitive and
showed the highest affinity [261–263]. When streptomycin was discovered [262], it was applied together
with penicillin [262], and the synergistic effect seemed to work [264]. However, this combination
provided a selective condition for MDR enterococci [263].
MDR enterococci strains are adapted to the gastrointestinal tract and can become the dominant
flora [265,266]. The first epidemic MDR Ent. faecium strain emerged from animal and commensal
strains [267,268]. Enterococci have been, and remained, a prominent Gram-positive pathogen in
the SENTRY (Antimicrobial Surveillance) Program from 1997 until now [269]. The most common
Enterococcus pathogen species are Ent. faecalis (64.7%) and Ent. faecium (29.0%) [269]. Enterococcus
faecum became the most important nosocomial pathogen, posing a growing clinical challenge because of
its rapidly evolving antibiotic resistance repertoire, practically against all clinically used antimicrobials.
Enterococci use many spectacular genetic strategies [270–272].
The MDR enterococci have individual combinations of genuine antibiotic resistance
mechanisms [38–41,273–278]. The resistance mechanisms include modification of drug targets [38],
inactivation of therapeutic agents [272,279,280], and overexpression of efflux pumps [38,281,282].
For more details, see Supplementary Material 2.
Their dynamic cell envelopes serve as their first line of defense against antimicrobials [264,283].
Peptidognt, ycan (PG), is a well-established target for antibiotics [284–287]. Components, like teichoic
acids, capsular polysaccharides (CPS), surface proteins, and phospholipids, can undergo modifications
and reduce the susceptibility to antibiotics [288–290].
4.2.1. Comparative Genomics of Enterococci: Species, Strains, Clades Resistance Groups
The recent way to identify of Enterococcus species has been based on a simple assay of the groEL
gene [291]. Comparative genomics showed that the MDR Ent. faecium genetic clade A1 [291–295] had
separated evolutionarily from the animal-adapted Ent. faecium [295–297] at about the same time as
penicillin and streptomycin were jointly introduced into clinical use [297].
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4.2.2. Clinically Adapted and Non-Clinical Enterococcus strains
Clinically adapted Enterococcus strains are still evolving from commensal strains, such as CC17
from Ent. foecium, but not from Ent. faecalis [266,267,298,299]. Clinical and non-clinical strains of
Ent. faecium have distinct structural and functional genomic features [300,301].
4.2.3. MDR Potential of Enterococci
For the genetics and genomics of ampicillin resistance in Ent. faecium, see the comprehensive
review by Zhang et al. [302]. Evolutionarily separated clinical strains intensively collect mobile
genetic elements, resulting in alterations in hyper-mutability that lends Ent. faecium its remarkable
genome plasticity [303]. Enterococci serve as donors of antibiotic resistance gene clusters, including
vancomycin resistance [304–309] and daptomycin resistance [310], to other Gram-positive pathogenic
micro-organisms including MRSA [310].
4.2.4. Vancomycin-resistant Enterococcus faecium VRE [298] as a Leading Cause of MDR
Hospital Infections
In the Enterococcus genus, the vancomycin resistance (VRE) gene clusters are classified into
nine types according to their gene sequences and the organization (reviewed by Chen and Xu) [311].
The latest review on the genomics of Ent. faecium VRE summarized the new insights into VRE evolution,
drug resistance, and hospital adaptation based on whole-genome sequencing [312,313].
Two genetically definable Ent. faecium populations are the hospital-adapted MDR (including
vancomycin-resistant) isolates (Clade A) [268,293,312,313] and vancomycin-susceptible commensal
strains (Clade B). The majority of five VRE isolates collected from different sites belong to VanA [269,314].
However, the isolate VanN [315], which had previously been found in chickens in Japan [316], and then
was also found in a hospitalized patient in Canada [317], emerged recently from a commensal (CladB)
isolate [268].
4.2.5. Enterococcus cecorum: An Example for the Recent Speedy Development of Antibiotic
Multiresistance in Genus Enterococcus
A normal commensal intestinal inhabitant is increasingly responsible for outbreaks of arthritis and
osteomyelitis in chickens. Since 2002, Ent. cecorum has been recognized as the causative pathogen of
enterococcal spondylitis (ES) [260,318–328]. Enterococcus cecorum was known as a harmless commensal
of the gastrointestinal tract of chickens. However, in the last one-and-a-half decades, new pathogenic
isolates of Ent. cecorum have been an increasingly significant cause of morbidity and mortality in broiler
chickens, and frequent outbreaks are reported, although an environmental reservoir for pathogenic
Ent. cecorum has not been found. Classical genetic analyses of Ent. cecorum demonstrated that strains
with increased pathogenicity are genetically related, and share several virulence genes and antibiotic
resistance genes, when compared to commensal strains. These pathogenic strains can be recovered
from retail meat, and they may serve as a reservoir for further spread of antimicrobial resistance among
other Enterococcus spp. [329]. For more details, see Supplementary Material 3.
4.2.6. Vancomycin, Vancomycin Resistance; Daptomycin, Daptomycin Resistance
Vancomycin is a non-ribosomal (NRP)-templated glycopeptide from Amycolatopsis orientalis [330,331].
It was used against Gram-positive targets, both intravenously and per os [332,333]. When taken by
mouth it is poorly absorbed. Vancomycin acts by inhibiting proper cell wall synthesis in Gram-positive
bacteria [38,334].
Vancomycin resistance: After the discovery and introduction of the omnipotent antibiotic
vancomycin, it was considered the last resort, or “card” in the “card game” of pharmaceutical science,
for Gram-positive pathogens [38]. Since the appearance of vancomycin-resistant enterococci strains
in the late 1980s, the number of resistances has been steadily rising, both in Enterococci [14,271,335],
Pathogens 2020, 9, 522 9 of 53
and Staphylococci [336,337]. Many resistance isolates appeared, often with life-threatening
consequences [337–340]. As an alternative to the generation of completely new substances, novel
approaches have focused on structural modifications of vancomycin to overcome these resistances and
to restore its efficacy against vancomycin-resistant enterococci [334,340]. The most recent knowledge
about the mechanism of vancomycin resistance has been summarized [341].
4.2.7. Daptomycin (DAP)
Daptomycin [342–352] is a cyclic anionic lipo-(dipepsi) lipopeptide, which includes three D-amino
acid residues (D-asparagine, D-alanine, and D-serine) linked to a hydrocarbon tail, ten carbons in
length, derived from decanoic acid [347]. It is biosynthesized by S. roseosporus from a soil sample
gathered from Mount Ararat, Armenia [348]. DAP was introduced as a new drug against S. aureus
(MRSA) and vancomycin-resistant enterococci (VRE), vancomycin-intermediate S. aureus (VISA),
and penicillin-resistant S. pneumoniae [344,349–351].
A spectacular genetic analysis, including transposon mutagenesis [352] and molecular
cloning [353], allowed discovery of the biosynthetic pathway of DAP. There are perspectives of
improved production of DAP by exploiting the potential of genetic manipulation of secondary
metabolite biosynthesis [354]. The total chemical synthesis has also been done [354].
4.2.8. Daptomycin Resistance DAP (R)
The discovery of the mode of action of daptomycin [355] helps to handle daptomycin resistance
problems. Intensive studies on daptomycin-resistant (DAP-R) mutants have also been discovered
in enterococci [349] [356,357]. This has resulted in revealing the mechanisms of DAP-R in different
Gram-positive bacteria [38–41,273], including B. subtilis [358], Enterococci [359–362], Ent. faecalis [361],
Ent. faecium [362–364], and S. aureus [365–368]. Mutations of DNA “mismatch repair” genes in a DAP-R
pleiotropic phenotype were discovered in a clinical isolate of Ent. faecium [369].
5. The Efforts to Discover Omnipotent (“Jolly Joker”) Antibiotics to Overcome MDR Problems
5.1. Teixobactin: The First Omnipotent (“Jolly Joker”) Antibiotic Active Against Gram-Positive Targets
The first antibiotic without detectable resistance was discovered in Kim Lewis’ laboratory.
Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of precursor peptidoglycan
lipid II and precursor of cell wall teichoic acid-lipid III (a) [370]. No S. aureus nor Mycobacterium
tuberculosis mutants have been found to be resistant to teixobactin so far [371]. However, resistance
mediated by D-stereospecific peptidases cannot be ruled out in the future [372]. Teixobactin is
a non-ribosomal peptide (NRP) antibiotic, which contains D-amino acid. The total synthesis and
structure–activity relationships of teixobactin have been conducted [373], and lactam and ring-expanded
analogs are also available [374]. Teixobactin provides a new perspective for using antibiotics in the
treatment of mycobacterial infections [375].
5.2. Narrow/Spectral Pluripotent Antimicrobial Peptides
We consider antimicrobial peptides (AMPs) as any polyamide (or even biopolymer with ester,
thioester, or otherwise modified backbone) that can be made on a contemporary chemical peptide
synthesizer, and that exerts antimicrobial activity [376]. The antibiotic-resistant bacteria show
widespread collateral sensitivity to antimicrobial peptides [377], as discussed later in detail.
AMPs are either of natural origin, such as those isolated from insects [378], or designed [379]
either by computer [380], following QASR-studies on the designer molecule [381] or after synthetic
(experimental) precursor manipulation [382]. The natural AMPs are part of the inherent immune
system in all known taxa but Archaea, [380,383], and many of them were found to be effective
against multiresistant pathogens, usually, with high selectivity [383] Encodings and models for
antimicrobial peptide classification for multi-resistant pathogens have then been developed, [383].
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Based on conclusions drawn from QSAR and in vitro bioassays the putative promising chemical
derivatives will then be structurally optimized [384]. Synthetic candidate derivatives including those
substituted with unusual amino acids [385] share unique features such as serum stability, lack of side
effects, and owing intracellular target specificity. The discovery of a new natural AMP molecule is
usually followed by quantitative structure/activity (QSAR) studies [381], and then the design and
optimization of analog molecules [379–385] then the best ones finally will chemically be synthesized.
The most promising molecular family is the proline-arginine rich peptide (PrAMP) [386]. including
pyrrochorrycins [386,387], apeadicins [388,389], and oncocins [390]. Some of them are in a preclinical
stage [391,392]. All of these are narrow spectral AMPs. Some were more efficient in vivo than in vitro,
supposedly due to cooperation with the innate immune system of the host to be protected [376,386–392].
5.3. Large Spectral Pluripotent (“Jolly Joker” Candidate) Non-Ribosomal Encoded (NRP) Biosynthetic
Antimicrobial Peptides
Omadacycline aminomethylcycline is a semisynthetic derivative of tetracycline, and it is active
against many Gram-negative bacteria and Gram-positives, including MRSA, S. aureus, S. pneumoniae,
β-hemolytic streptococci, Enterococcus VRE, and Enterobacteriaceae in vitro [393] and in vivo in
clinical practice [394]. Similar activity has also been found in the thermostable antimicrobial peptide
discovered in Hungary in Xenorhabdus budapestensis and X. szentirmaii [31,395–399] and later identified
as fabclavine [400–405].
5.4. Efflux Pump Inhibitors (EPIs)
Efflux pump inhibitors (EPIs) had great potential, but the putative drug candidates were toxic [406].
Two new carbapenem–β-Lactamase inhibitor combinations were introduced [151]. In the last years,
several hundred thousand people developed multidrug-resistant tuberculosis (MDR-TB), requiring
a new effective treatment. It was found that efflux pumps play an important role in the evolution
of drug resistance. New strategies are required to mitigate the consequences of the activity of efflux
pumps [130].
6. Adaptive Evolution: Trends and Mechanisms in Relation to MDR-Posed Danger
Antibiotic multiresistance has an obviously increasing worldwide tendency an evolutionary trend.
The real question is whether the evolution of MDR is an irreversible one-way street.
6.1. Resistance vs. Persistence: Darwinian and Lamarckian Approaches
The proper approach for trying to slow down the rapid evolution of resistant bacteria requires
a full understanding of the mechanisms of adaptive evolution [68,407–409]. The problem with the
similarities between resistant and tolerant phenotypes is that tolerance can be associated with the
failure of antibiotic treatments [410]. The correct and precise definitions of the terms of tolerance,
persistence, persistent, and resistance have been provided in “opinion papers” [410] and confirmed by
the Consensus Statement found in Balaban and her associates [411].
The phenotypic similarities between resistance and persistence led to Darwinian- and
Neo-Lamarckian-inspired research approaches. Resistance is a phenotypic expression of a resistance
allele and is specific for an antibiotic with a unique structure. This allows the microorganism to grow
in the constant presence of the antibiotic within a concentration range [412].
This can be quantitatively characterized by a Minimal Inhibiting Concentration (MIC). On the
other hand, tolerance (the synonym of persistence) [413] provides a general, not antibiotic-specific
protection. Inheritable persistence is a pleiotropic phenotype with loss-of-function alleles from many
genes with completely different functions [414], called toleromes by Brauner et al. [410].
Non-inherited persistence is inducible [415–417], fitness-decreasing [418], and in a dormant
stage [413]. This is the phenotype of the epigenetic subpopulation [419–421] that remains in the culture
after the actively respiring bacteria have been vanquished by antibiotics [422,423].
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The Minimum Duration for killing (MDK99) is the quantitative parameter designed to evaluate the
tolerance level of the population treated with antibiotics [410]. The epigenetic persisting subpopulation,
with a non-inherited persistent phenotype, has a clear adaptive value [424–427]. It serves as a sheltered
evolutionary reservoir [428] from which antibiotic-resistant mutants may emerge [426,427]. Potentially,
“persistence invites resistance” [429], but it appears that persistence may, but not must, precede
resistance [429–431]. Persistence-based antibiotic resistance research efforts are of key importance from
the aspect of elaborating anti-persistence strategies [432–441], but this is out of the scope of this review.
6.2. An Introduction to Experimental Evolution
The 60-year history of genomic research, which helped reconstruct mobile genetic elements
harboring genes responsible for multidrug resistance of pathogens, has recently been reviewed [407,442].
The spread of many multidrug-resistant (MDR) bacteria is predominantly clonal. Interestingly,
international clones/sequence types (STs) of most pathogens emerged and disseminated during the
last three decades [443]. This kind of evolutionary processes can be monitored or experimentally
recapitulated. Bottlenecks reduce the size of the gene pool within populations of all, with implications
for their subsequent survival. By reducing genetic diversity, bottlenecks may alter individual
or population-wide adaptive potential [444]. Here we discuss some other aspects directed to
antibiotic resistance.
Resistance Evolution and Mobile Genetic Elements in Enterococci
Gilmore and his associates wanted to determine how the enormous accretion of mobile elements
affect the competitive growth of enterococci in the gastrointestinal tract consortium [303,445].
They observed that the prototype clinical isolate strain (V583) was actively killed by the gastrointestinal
tract flora, while commensal enterococci flourished. They found that the death of V583 resulted
from lethal crosstalk between accumulated mobile elements, and that this crosstalk was induced by
a heptapeptide pheromone produced by native Ent. faecalis present in the fecal consortium [303].
They concluded the accumulation of mobile elements in hospital isolates of enterococci can include those
that are incompatible with native flora. That is, in the absence of antibiotics, wild type (commensal)
bacteria can win the competition with MDR pathogens.
6.3. Resistance Is Not a Positive Selection Marker in a Commensal Niche—The Lesson Learned from Population
Genetics and Monitoring Evolutionary Processes
The virulent, globally disseminated, multidrug-resistant lineage ST131 of E. coli can cause urinary
tract infections and bacteremia [443,444]. To differentiate ST131 from the larger E. coli population
associated with a disease, Kallonen and his colleagues isolated samples from various parts of
England for genomic analysis under the framework of a systematic 11-year hospital-based survey [446].
They concluded that antibiotic resistance must not have been the predominant reason for the prevalence
of E. coli lineages in this population, but the frequency of E. coli lineages in an invasive disease was
driven by negative frequency-dependent selection, acting in the commensal niche outside of the
hospitals. This research team later showed that the predominant multidrug resistant E. coli clones,
under the influence of negative frequency-dependent selection, are prevented from rising to dominance
in a population [447].
In a long-term (2001–2014), worldwide analysis of enterococci and vancomycin-resistant
enterococci (VRE) causing invasive infections, Mendes and his team evaluated the prevalence
and in vitro susceptibility of enterococci and VRE in bloodstream infections in European and US
hospitals [448]. Through a SENTRY Surveillance Program, Mendes and his associates found that the
VRE rates among Ent. faecium increased both in Europe and the USA. The multidrug-resistant (MDR)
phenotype was a positive selective trait of antibiotic stress under hospital conditions.
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6.4. The Loading Capacity of the Bacterial Genome Is Limited—The Lesson Learned from
Experimental Evolution
Escherichia coli is an ideal organism for experimental evolution. Most changes to its metabolic
network that survived over the past 100 million years, which are adapted genetically to the
environment, are due to horizontal gene transfer, with a very low contribution from horizontal
gene transference [407,442]. Experimental microbial evolution studies use controlled laboratory
populations to evaluate the mechanisms of evolution and are based on molecular, genomic, and maybe
transcriptomic and proteogenomic analysis over several generations of evolving populations in
controlled, pre-established conditions in a morbidostat [449–451] or in a DiVERGE [452]. The srecently
developed technolog, enables researchers to carry out testing on empirical prediction ns of a given
evolutionary theory [453,454]. The data from the literature gave an impression that a new antbitoc
resistance is a positive selection marker in antibiotic stress conditions but is a negative selection marker
in commensal milieu (as demonstrated on Figure 2A).
6.4.1. Evolutionary Trends in The Presence of Antibiotics
Toprak and his associates experimentally recapitulated the evolution of antibiotic resistance
developed in E. coli against several different antibiotics, and they found a gradual increase in
resistance levels of each antibiotic tested during the experimental period [455]. The whole-genome
sequencing of the evolved strains revealed mutations including resistant ones to the given drug or
resistant ones to more than one drug. Resistance could be developed either in a stepwise manner in
replicates (trimethoprim) or via diverse combinations of mutations in different genes (chloramphenicol
and doxycycline). For interactions between the presence of an antibiotic and resistance evolution,
the evolutionary dynamics were monitored by whole-genome deep sequencing every 3 to 4 days in
another Gram-negative pathogen organism, P. aeruginosa. During the experimental period, the resistance
level to colistin increased by one order of magnitude in 10 days and two orders of magnitude in 20 days,
supposedly due to mutations in the mutS mutator gene [456].
Resistance, Fitness, and Compensatory Mutations
The antimicrobial pressure may drive the evolution of its resistance, which may be associated
with reduced bacterial fitness. There is evidence that the probable “evolutionary price” of a
new antibiotic resistance is lowering fitness, and it must be determined genetically [457–460].
The phenotypic consequences are reflected in the geometry adaptations [461,462]. However,
compensatory mutations [461] may change the pattern and might be an explanation of the dissemination
of colistin-resistant A. baumannii isolates [63,463]. This might be an explanation for the dissemination
of colistin-resistant A. baumannii isolates [203]. Using precise, high-throughput fitness measurements
for genome-wide E. coli gene deletion strains, with eight antibiotics, the width of the distribution of
fitness effects (so-called DFE) mutations, which occur spontaneously from one antibiotic to another,
is lower than in the absence of the antibiotic stress [462]. Unlike the DFE mutations, the magnitude of
the changes in tolerated drug concentration, resulting from genome-wide mutations, are similar for
most drugs but are exceptionally small [464].
Collateral Sensitivity
In a large-scale laboratory evolutionary experiment, Lázár and her associates discovered a novel
trend in the evolution of antibiotic hypersensitivity in E. coli called collateral sensitivity [377,465–468].
Some populations which became adapted to amino-glycosides have especially low fitness in the
presence of several other antibiotics. The whole-genome sequences of 63 independently evolved
amino-glycoside-resistant strains demonstrated multiple mechanisms based on reduced proton-motive
force (PMF) through the inner membrane. The comparison of captured determinants of the
antibiotic cross-resistance interaction network demonstrated that convergent molecular evolution
was predominant across antibiotic treatments, and the resistance encoding mutations simultaneously
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enhanced sensitivity to many other drugs [465]. This phenomenon is called collateral sensitivity [and
illustrated on Figure 2B. As mentioned before, antibiotic-resistant bacteria show widespread collateral
sensitivity to antimicrobial peptides [377].
Antibiotic and Antimicrobial Resistance Genes are of Different Mobility Patterns
The antibiotic-resistant bacteria not only showed an unexpectedly high frequency of collateral
sensitivity to antimicrobial peptides, while cross-resistances between the strains were rather rare [390],
but clinically relevant multidrug-resistance mutations also increased susceptibility to antimicrobial
peptides. As for mechanisms, collateral sensitivity in multidrug-resistant bacteria arise partly through
regulatory changes shaping the lipopolysaccharide composition of the bacterial outer membrane.
This information allows the identification of antimicrobial peptide and antibiotic combinations that
enhance antibiotic activity against multidrug-resistant bacteria and slow down de novo evolution
of resistance [377,468]. Furthermore, while the antimicrobial peptide (AMP) resistance genes are
widespread in the gut microbiome, their rate of horizontal transfer is lower than that of antibiotic
resistance genes [469]. Gut microbiota culturing and functional metagenomics have revealed that AMP
resistance genes originating from phylogenetically distant bacteria have only a limited potential to
confer resistance in E. coli, an intrinsically susceptible species [469].
6.4.2. Evolutionary Trends of Antibiotic Resistance in the Absence of Antibiotic Exposure
Antibiotic use is the main driver in the emergence of antibiotic resistance. In a set of
experiments with E. coli, it was demonstrated that in the absence of an antibiotic and resistance
evolution, drug-resistance frequently declined within 480 generations during exposure to an
antibiotic-free environment.
The extent of resistance declination seemed antibiotic-specific and driven by mutations influencing
both the resistance level and fitness probably pleiotropically [469]. It was concluded that a phenotypic
reversion to the antibiotic-sensitive state may be mediated by the acquisition of additional mutations
while maintaining the original resistance mutations [469]. This result might be an important argument
against the selective virtue of antibiotic resistance in general.
However, in a set of experiments on another Gram-negative pathogen, P. aeruginosa, an opposite
trend was demonstrated. It is difficult to interpret this contradiction. It was demonstrated that
selection in the absence of antibiotics did co-select for decreased susceptibility to several antibiotics.
This was considered as experimental evidence confirming the selective virtue of antibiotic resistance in
a commensal niche [468]. The interpretation of these results by the authors is that resistance evolved
coincidentally in response to other selective pressures. Thus, genetic adaptation of bacteria to natural
environments may drive resistance evolution by generating a pool of resistance mutations, where
selection could act to enrich resistant mutants when antibiotic exposure occurs [470].
6.4.3. Phylogenetic Limitations: Species Specificity of the Antibiotic Resistance Genes
Recent studies on transferring resistance-conferring mutations and full resistance genes into E. coli,
from and to closely related species, have not been very successful. Resistance mutations originated
from one bacterial species and transferred to another, and they rarely invoke a resistance phenotype.
More frequently, the yield was drug hypersensitivity in close relatives, since the new gene could not fit
the epistatic system of the new host, as was demonstrated in the case of the transferred aminoglycoside
resistance (trkH) gene [471].
6.5. The CRISPR/Cas Bacterial Immune System: A Molecular Tool to Get Rid of Unwanted
Antibiotic Resistance
Bacteria and Archaea have developed a system based on clustered, regularly interspaced, short
palindromic repeats (CRISPR) from peculiar genetic loci. These repeats provide acquired immunity
against viruses and plasmids by targeting the nucleic acid in a sequence-specific manner [472].
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These hypervariable loci take up genetic material from invasive elements and build up inheritable
DNA-encoded immunity over time. It was demonstrated that the S. thermophilus CRISPR1/Cas system
can also naturally acquire spacers from a self-replicating plasmid containing an antibiotic-resistance
gene, leading to plasmid loss. The most recent evolutionary classification of CRISPR-Cas systems
and cas genes includes two classes, 6 types, and 33 subtypes. The discovery of numerous derived
CRISPR-Cas variants is often associated with mobile genetic elements that lack the nucleases required
for interference [473].
7. Clonally Evolving Pan-Genomic ESKAPE Pathogens
7.1. Pseudomonas aeruginosa: A Pan-Genomic Hotbed of Multidrug Resistance
The latest review on antibiotic resistance mechanisms in P. aeruginosa and alternative therapeutic
strategies came out last year [474]. Our latest knowledge about the lifestyle of P. aeruginosa (for
taxonomy: see Wikipedia) is that of a ubiquitous [475], invasive [476], opportunistic [477–480],
facultative, pathogenic bacterium species. It can cause diseases in plant and animal species, as well as
in humans [481], which has recently been summarized [482]. As a consequence of its evolutionary
plasticity [483], based on open genome expandability [484–487], it is armored with a full arsenal of
antibiotic multiresistance [3,488,489]. The majority of MDR P. aeruginosa displays a wide repertoire of
antibiotic resistance mechanisms, including posttranslational modification of drug targets [490–492],
enzymatic inactivation of antibiotic molecules [493], encoding genes of carbapenem-resistance
preferably those coding for metallo-β-lactamase; overexpressing efflux pumps [494–496], and showing
strong ability to form a biofilm [497–499].
Pseudomonas aeruginosa is one of the two pangenomic [499,500], Gram-negative pathogenic species,
which has permanently acquired MDR encoding genes. It is a threatening source of resistance genes,
which are transmittable via horizontal gene transfer [339,501].
7.1.1. A Shortlist of Intrinsic and Acquired Antibiotic Resistance in P. aeruginosa
The most recent overviews [487,489] provides “an ocular perspective” of the different mechanisms
of antibiotic resistance in P. aeruginosa. Most strains are intrinsically resistant to third-generation
cephalosporins due to chromosomal-encoded C beta-lactamase and AmpC [488,501]. The original
intrinsic MDR-arsenal includes the production of beta-lactamases, loss of outer membrane proteins [500],
and up-regulation of efflux pumps [502–507]. This species also acquired resistance to aminoglycosides
and fluoroquinolones [487]. One of the acquired enzymes taken-up by P. aeruginosa, Pseudomonas
extended resistance (PER) [508–511], a class of extended-spectrum beta-lactamase (ESBL), occurs less
frequently but still is of clinical importance [512,513].
Pseudomonas aeruginosa uses different mechanisms that can jointly contribute to its multiresistant
phenotype [512] and multidrug efflux systems [492,495,496,514,515]. All of this makes P. aeruginosa
extremely invasive. The rapidly increasing number of new P. aeruginosa isolates of MDR, XDR, and PDR
phenotypes severely reduces the antibiotic therapy options available [3]. Valuation of the economic
cost of antimicrobial resistance (AMR) is important for decision making and should be estimated
accurately, [516]. Colistin, which acts on outer membranes of bacteria resulting in its permeability
and cell-death, was suggested five years ago as a salvage therapy in the treatment of life-threatening
infections due to MDR P. aeruginosa blood-stream infections (BSI) [517]. Articles and reviews on
resistance problems appeared one year later [518] and have been appearing since [205,214–217].
7.1.2. Pseudomonas Genetics and Genomics
Genetics: Most genes of intrinsic resistance are on the chromosome, including multidrug efflux
pumps and enzymes responsible for resistance to beta-lactam and aminoglycoside antibiotics [519].
Genomics: A challenging option, provided by the next-generation whole-genome sequencing,
as an approach to better understand and combat antibiotic resistomes [520], has been beneficially used
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in Pseudomonas research, as exemplified by Cao et al. [521]. An international consortium has been
continuously providing comparative genomic information [522,523] and the prognosis [500] for clinical
use. In addition. an antimicrobial resistance prediction concluded from the comparative genomics
data of comparative sequence analysis of all available drug-resistant P. aeruginosa genomes could be
realized [486,501,516,522,523].
Ramanathan and his associates studied single-nucleotide polymorphisms (SNPs) in ten
multiantibiotic resistant P. aeruginosa clinical isolates [519]. Non-synonymous single-nucleotide
polymorphisms (nsSNPs) were found in more clinical isolates compared to the reference genome
(PAO1). The nsSNPs identified in the multidrug-resistant clinical isolates were found to alter a single
amino acid in several antibiotic-resistant genes. They also found mutations in genes encoding efflux
pump systems, cell wall, DNA replication, and genes involved in repair mechanisms. Furthermore,
nucleotide deletions in the genome and mutations leading to a generation of stop codons were also
observed in the antibiotic-resistant clinical isolates, and in specific mutations within antibiotic-resistant
genes, compared to the susceptible strain of the same bacterial species [519].
7.1.3. Transcriptomics
So far, we have detailed knowledge of the behavior of P. aeruginosa under standard laboratory
conditions, but we only have a superficial understanding of bacterial functions and behaviors during
human infection. However, a recent study on transcriptomes in human infection revealed that multiple
genes known to confer antibiotic resistance had substantially higher expression in human infection
than under laboratory conditions [524].
7.1.4. Resistance Phenotypes
The first comprehensive review on this subject was published by Kempf and Rolain [525].
Mutations in pmrB confer cross-resistance between the LptD inhibitor POL7080 and colistin in
P. aeruginosa [217]. Integrated whole-genome screening revealed that P. aeruginosa virulence genes use
multiple disease models, and the pathogenicity is host-specific [8]. Biofilm formation is an important
part of the pathogen strategy of this bacterium [526]. A list (incomplete) of Pseudomonas-caused human
diseases is discussed in Supplementary Material 5.
7.2. Acinetobacter baumannii
7.2.1. Species with a Gradually Expanding (Open) Pangenome
The bacterium Micrococcus calcoaceticus was isolated from soil by enrichment in a calcium-acetate-
containing minimal medium [527]. It was finally moved to Moraxella [528] as a single representative
of genus Acinetobacter in Bergey’s Manual [529] under the name of A. calcoaceticus (type strain ATCC
23055) [529]. Acinetobacter baumannii was designated taxonomically after appearing as a human
pathogen [530–533]. Acinetobacter baumannii is also a veterinary pathogen [534–538], but, unlike
P. aeruginosa, it has not appeared as a plant pathogen. Acinetobacter baumannii is a very successful
pathogen [539]. WHO declared that A. baumannii is one of the two most serious pangenomic ESKAPE
organisms [540]. Since then, the rapid global evolution of MDR in A. baumannii has been carefully
monitored, and clonal lineages of old and new isolates have been revealed [541]. Two long-term
international global surveys have recently been carried out on A. baumannii as a potential health risk
factor, as reported by Gales et al. and Flamm et al. [540,541].
7.2.2. Resistance Mechanisms and Diseases
The mechanisms of disease caused by A. baumannii strains have recently been reviewed by
Morris et al. [8]. The latest review on the resistance mechanisms of A. baumannii [542] focuses on
XDR resistance.
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As for its resistance mechanisms, tigecycline efflux was described as a mechanism for non-
susceptibility in A. baumannii. In addition, a deletion of TnAbaR23 resulted in significant antibiogram
changes in a multidrug-resistant A. baumannii strain [543]. For more information see Supplementary
Material 6.
7.2.3. Genetic Dissection of Colistin Resistance in A. baumannii: Trebosc et al., 2019
The transcriptional regulator PmrA was considered as the only potential drug target to restore
colistin efficacy in A. baumannii [510], but the deletion of pmrA, the gene responsible for overexpression
of the phosphoethanolamine, PetN, only restored susceptibility in a few strains. A detailed genetic
analysis revealed a new colistin resistance mechanism mediated by genomic integration of the ISAbaI
insertion element upstream of the PmrC homolog (eptA), leading to its overexpression. The gene
eptA is present in each international clone 2 clinical strain, and a duplicated ISAbaI-eptA cassette
was present in at least one clinical isolate, thus indicating this colistin resistance determinant may be
embedded in a mobile genetic element [216].
7.2.4. Genetics Toolkits to Becoming Multiresistant
Acinetobacter baumannii, like other non-glucose-fermenting Gram-negative species such as
P. aeruginosa, has increasingly been acquiring carbapenem resistance [544,545]. An argument against the
worries [546] that A. baumannii increases the risk of carbapenemase spread in general, since horizontal
resistance gene the transfer can occur between Gram-negative species, regardless of their ability to
ferment glucose [545], is that experimentally transferred resistance mutations from other species to
E. coli have been mostly silent, and frequently yield drug hypersensitivity [469].
7.2.5. Sword of Damocles: Clonal Evolution, Global Spread, and Epidemic Potential of A. baumannii
The different antibiotic resistance genes are organized into resistance islands in the genome of
A. baumannii. The impression of the reviewers is that the MDR, XDR, and PDR must not be considered
as simple collections of different antibiotic resistances, but they may represent a coordinated system
based on sophisticated genetic background and genomic organizations. Based on the evolutionary
analysis of six housekeeping genes, A. baumannii is of monophyletic origin [531,546]. Originally three
predominant pathogen clones, called ‘international clonal lineages’ (ICLs), were known as being
responsible for hospital outbreaks worldwide [547]. The monophyletic status of ICLs 1 and 2 have also
been shown [38,548]. As reviewed first by Dijkshoorn et al. [546], the genome of a representative ICL1
(AYE) [549–551] strains include 52 genes associated with resistance to anti-microbial drugs, and 45 are
localized in an 86 kb resistance island called AbaR5 [552]. ABAR1 is also present in other A. baumannii
strains, but at a much smaller size. The presence of an extraordinary 22 gene-cassette coding for
transposases and insertion sequences may be responsible for the acquisition of resistance genes into
the AbaR1 island of the AYE ICL1-type strain [543]. Almost half are orthologous to coding sequences
of Pseudomonas [546].
7.2.6. Genome Plasticity
The Acinetobacter baumannii calcoaceticus complex is considered as a species with an open
pan-genome and is well-defined on Wikipedia. The complete genome [553–555] includes the core
genome (genes present in all isolates) with extreme antibiotic resistance traits [554]. In addition,
the accessory genome [555], including the genes absent from one or more isolates, or unique to
a given isolate, also contains hosts antibiotic resistance genes but in different arrangements [555].
Antibiotic resistance genes are located both in the core and the accessory genomes [556]. In the latter,
they were found in alien islands or flanked by integrases, transposases, or insertion sequences [556].
They must be acquired via horizontal gene transfer from other Acinetobacter strains to colonize the same
environment [556]. The first detailed genomic analyses revealed that the existing A. baumannii clinical
population consists of low-grade pathogens, whose pathogenicity relies mainly on an ability to persist
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in the hospital setting and survive antibiotic treatment [4]. This analysis led to the conclusion that
A. baumannii has a high capacity to acquire new genetic determinants and displays an open pan-genome.
This feature may have played a crucial role in the evolution of this human opportunistic pathogen
towards clinical success [4]. The whole pangenome of A. baumannii consists of >8800 orthologous
coding sequences, and it has exponentially been increasing as new genomes become available (an
open pan-genome), mainly due to unique accessory genomes of different isolates enriched with
acquired genes of transport and transcription regulation functions [4]. Since then, at least 15 complete,
and 180 draft, chromosomal A. baumannii genomes, 31 plasmids, and six bacteriophage sequences have
been available on the NCBI database, together with those of other species of the genus, and antibiotic
treatment induces important genes [557]. The open pan-genome of A. baumannii also includes lots
of plasmids, transposons, integrons, and genomic islands, which may contribute to the evolutionary
success of this clinical pathogen. This is particularly true in the acquisition of multidrug resistance
determinants [5], a tool for redefining this, and other, pathogenic bacterium species [162,547,557,558].
7.2.7. Will the Epidemic Threat Be Materialized?
The population structure of A. baumannii comprises of a set of expanding multiresistant clones
raised from an ancestral susceptible genetic pool [559–561], confirming that A. baumannii used to
have low phylogenetic diversity, providing a narrow evolutionary bottleneck through which a
micro-evolutionary tree with many branches has emerged [546]. Making this metaphor complete,
each branch of that tree carries “dangerous fruit” called antibiotic-resistance (ABR) genes. All the other
known Acinetobacter species are harmless soil-inhabiting ones [546].
Until recent years, A. baumannii has been almost exclusively isolated from locations of antibiotic
stress conditions, that is, in hospital environments, (especially from intensive care units of hospitals) and
veterinary clinics [562–564]. However, in 2017, A. baumannii DSM30011 was obtained from the resinous
desert shrub guayule and may be considered as a “copy” of the first isolate, and whole-genome
sequencing and phylogenetic analysis based on core genes confirmed DSM30011 affiliation to
A. baumannii [565]. No antimicrobial resistance islands were identified in DSM30011, agreeing with a
general antimicrobial susceptibility phenotype. The marginal ampicillin resistance of DSM30011 most
likely derived from chromosomal ADC-type ampC and blaOXA-51-type genes [566]. The environmental
Acinetobacter baumannii isolate DSM30011 reveals clues into the preantibiotic era genome diversity,
virulence potential, and niche range of a predominant nosocomial pathogen [567] armed with efficient
multidrug efflux pumps [567].
The “branches” of the original “tall” “micro evolutionary tree” are rather “long.” ln the frame of a
SENTRY study [543], Acinetobacter clinical isolates from 10 South Asian and Pacific countries were
tested for being non-susceptible to imipenem or meropenem and positive for OXA-23-, OXA-24/40-,
OXA-58-, and MBL-encoding genes [540,541]. The sword of Damocles (a global Acinetobacter epidemic)
is still possible, but has not yet been dropped down.
8. Concluding Remarks
We must apologize for omitting so many excellent publications from this field because of
space limits.
8.1. Forcasts Based On Evolutionary Data
8.1.1. The Main Question
Whether the post-antibiotic era is at the gate, or there is a chance to prevent its coming, is the
question of questions. The literature convinced us that the trend of the global expansion of clonally
spreading MDR and XDR pathogens is not irreversible. The post-antibiotic era is not inevitable. Let us
discuss the arguments for and against these statements.
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8.1.2. The “Combat Scenario”
Nature and science have long been battling. Science produces antibiotics, nature presents
pathogens with resistances. Nature has gradually become more sophisticated and better organized.
The MDR or XDR phenotype cannot be considered as a brute summary of the expression of ad hoc
collected (intrinsic and acquired) antibiotic resistance alleles. MDR (or XDR) represents a concerted
phenotypic expression of structurally and functionally organized (operons, cassettes, integrons),
and coordinated (resistomes) resistance alleles, which had been selected by the evolution. Both the
intrinsic occurrence and the uptake of resistance alleles are random.
8.1.3. Adaptive Evolution
The selective drives acting in the commensal niche and those acting in a milieu under selective
(antibiotic) pressure are different. A neutral mutant allele, including those encoding resistance, in a
commensal niche may be fixed in the population on the condition that it does not display a heavy
genetic load, that is it does not express a negative fitness affecting (DFE) phenotype]. That is, it does not
have either a positive or a negative selective value. Therefore, new antibiotic resistances are expected
to appear in the future as in the past.
Neutral mutant alleles, including resistance-encoding ones, in a commensal niche may be fixed in
the population on the condition that it does not display a heavy genetic load, or if it does not express
negative fitness affecting (DFE) phenotype. That is, it does not have either a positive or negative a
selective value. Therefore, new antibiotic resistances are expected to appear in the future, as in the past.
A mutant allele with a strong antibiotic resistance phenotype will expectedly be lost, or at least
prevented from domination, or selectively lost in commensal conditions if it represents a heavy
genetic load. This phenomenon is demonstrated in the monitoring studies on Gram-negative and
Gram-positive MDR pathogens. However, the same allele will be enriched in the population up to
100% under selective (antibiotic) stress conditions, either in a hospital environment or in the laboratory.
8.1.4. The “Dialectics” of Resistance and Sensitivity
There are exceptional situations when the same gene can act as a resistance or a sensitivity gene,
in the same species, depending upon genetic background (Supplementary Material 4).
8.1.5. Collateral Sensitivity: A Biochemically Proven Limiting Factor in MDR Evolution
For evolutionary success (winning the “permanent war”), the pathogen needs to carry strong and
heavy “weapons” (MDR combinations), which also increases the genetic load. The rediscovery, genomic,
and evolutionary interpretation of the collateral sensitivity is the most important experimental proof
that the resistance capacity of a bacterium is limited. It means that “trees cannot grow up to the sky”.
The credibility of this discovery is also supported by biochemical evidence]. The molecular technique
for getting rid of an unwanted resistance is probably the CRISPR/Cas Bacterial Immune System.
This conception is illustrated in an allegoric way on Figure 2. The higher resistance level makes
the pathogen stronger in selective but weaker in non-selective (commensal) conditions. (Figure 2A–H).
This explains collateral sensitivity as well. A limited number of resistances can be harbored, but not
more. If the pathogen gains a new one (#11 in Figure 2G, and #13 in Figure 2H) it must get rid of
another one (#1 Figure 2G and #3 on Figure 2H). The data in the last report of the HAI Consortium on
changes in antibiotic resistance profiles of MRSA clones in the USA indirectly confirm that collateral
sensitivity is not a laboratory artifact [256].
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Figure 1. Illustration of the competition between new antbiotics and invoed resistances. The “Card
Game” betw en science (designers of a tibi tics) and nature (antibiotic resistance profile designing
pathoge s). Legend to Fi ure 1. Both with the Gram-negative (left) and the Gram positive (right)
“card tables”, the respective uppermost row represents the cards in the hands of science (antibiotics,
antimicrobial peptides), and the lowest line is the cards (resistances) in the hands of nature. Science
put down the “first card”, penicillin (let us refer to it as a “Jack”). However, nature replied with the
“wedge”, called penicillin-resistance, acting as a trump-card to hit “Jack” in both the Gram-negative
and the Gram-positive “card games”. Then, science put down its’ “queen” to hit this “wedge” in
both “card-games”: the beta-lactams, such as the amino-penicillin family for the Gram-negative and
methicillin for Gram-positive “card games”. They worked properly until nature produced new “wedges”
(resistances): the extended spectral beta-lactamases (ESBL) and methicillin-resistance (MRSA), acting as
trump cards in the Gram-negative and the Gram-positive “card games”, respectively. Then, science
put down “kings” to hit the queen-hitting wedges: carbapenems to overrule ESBL, and vancomycin
to overrule MRSA in Gram-negative and Gram-positive “card games”, respectively. Soon after the
introduction of the “kings”, nature produced king-hitting trump card “wedges” such as CRE (carbapenem
resistance) in the Gram-negatives and vancomycin-resistance (VRE in Enterococci and VRS in Staphs) in
the Gram-positive “card games”. “Ace” antibiotics have become urgently needed. The Science took out
the “old card” colistin (polymyxin) as an “ace” against the Gram-negative, and the newly discovered
antimicrobial peptide against Gram-positives. However, Mother Nature produced new “wedges” again,
the colistin- and daptomycin- resistance bacteria. As the game ramps up, “Jolly Jokers” are now needed
and being searched for. The first potential “Jolly Joker”, teixobactin [382], was active on Gram-positives.
It was isolated and identified 4 years ago, and since then has not invoked resistance. Additional “Jolly
Joker” antibiotics acting against both Gram-positive and Gram-negative targets are still needed.
8.1.6. Counterarguments
An experimentally supported counter-argument is compensatory evolution [461]. Another fact
taken into considerations is that neither E. coli nor S. aureus is a pangenomic species. It is unknown
whether the pangenomic pathogen species (A. baumannii [532], P. aeruginosa [462], K. pneumoniae [225])
were able to compensate for the genetic load by expanding their genome. They can withstand an
increased number of resistances by exploiting their evolutionary plasticity and disseminate clonally or
polyclonally. They serve as a permanent hotbed of other MDR pathogens [439]. Fortunately, there are
phylogenetic barriers to horizontal transfer of antimicrobial peptide resistance genes in the human gut
microbiota [466,469]. Another optimistic message from experimental evolution is that the majority
of antibiotic resistance genes are species-specific and do not increase, but rather decrease, the MDR
phenotype if they are uptaken by E. coli. [469].
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phenomenon of collateral sensitivity seems to support this forecast. When the hypothetical 
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bacterium is llustra ed as a seven-h aded monster. (A) demonstrati n of different trends of adaptive
evolution n commensal a d hospital environments. (A) Each new antibiotic resistance ([A]—[0 R];
[B]—[1 R];[C]—[2 R]; [D]—[3 R]; [E]—[4 R]; [A]—[5 R]) elevates the genetic load and reduces fitness,
which makes the pathogen more vulnerable in antibiotic-free (commensal) conditions symbolized as
nature (A). Under antibiotic stress conditions, hospital resistance as a positive selection marker makes
the pathogen even more powerful and dangerous. (A) A pathogen without antibiotic resistance (R = 0)
has similar strength in the hospital and in nature (the pathogen is symbolized as a wild cat). (B) One
antibiotic resistance (R = 1) (#1) makes the pathogen a little stronger (an ounce) in the hospital and a
little weaker (bobcat) in nature. (E,F) The more resistant alleles (#1, #3, #5, #6 and #1, #3, #5, #6. #7) that
are present, the more strength in the hospital (symbolized ounce and lion, respectively) and elevated
weakness (“baby cats”) in nature. (B) Demonstration of collateral sensitivity. (G,H) The load-bearing
potential must be limited, at least the phenomenon of collateral sensitivity seems to support this forecast.
When the hypothetical seven-fold resistant pathogen (resistant to antibiotics #1, #3, #5 #6, #7, #8, and #9)
acquires an 8th (#11*, (G)) and a 9th (#13*, (G,H)), resista ce, respectively, it drops out resistance #1
and #3, respectively.
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Theoretically, however, epidemics caused by any of the three pangenomic pathogenic species
might break out at any time. Our view is that since all but K. pneumoniae should be considered as a
first-grade pathogen, the epidemic danger may not be immediate. However, immunocompromised
patients in hospital environments are at permanent risk.
8.2. Statistic-Based Conclusions from the Frequencies of MDR-Related Publications in PubMed
We drew some conclusions from the temporal distribution of MDR literature in the last decade.
The publications convinced us that only the monoclonal-spreading pangenomic pathogen species
display a global epidemic threat. Naturally, it should not be underestimated. However, the nearly
even temporal distribution of the literature seems to be an indicator of a permanently dramatic, rather
than an alarming, situation.
All three tables should be evaluated together. Table 1A–C shows a dramatic increase in the
number of reports on new resistant isolates of each Gram-negative ESKAPE species. No report was
found about XDR or PDR, concerning the non-pan-genomic “ESKAPE Club members” (see also
Table 2). When we entered MDR/XDR, or pan-resistant, and S. aureus or Enterococcus, we invoked
few (24 and 6, respectively) references. However, none of those strains discussed in the articles
would qualify as pan-resistant or XDR. We propose that the plausible explanation must be collateral
sensitivity. The polyclonally spreading pathogens also display a permanent threat but would not cause
epidemics. As far as we know, there is no clonally disseminating pan-genomic Gram-positive pathogen
species. In addition, we found few references about Gram-positive XDR isolates, although <5% of
the publications about PDR isolates are cited by PubMed. However, the evidence on pan-genomic
isolates contradicts this conclusion. We suppose that there are other unrevealed resistance mechanisms
based in the versatility of Gram-positive cell walls, which may provide more general protection to the
Gram-positive organisms expressing the respective alleles, but we do not suppose that this kind of
resistance could be disseminated globally.
Table 1. Temporal distribution of PubMed cited reviews on MDR-related issues in Gram-negative
ESKAPE bacteria.
A. Temporal Distribution of PubMed Cited Reviews on ESBL, Carbapenem, and Colistin Resistance in
Gram-negative (Old List) ESKAPE bacteria
Questions to PubMed (Entries)
Answers (Items): Articles: A, Reviews: R)
ALL 2019 2018 2009 2001
A R R R R R
Beta-lactams 130,408 9814 121 325 345 332
Extended Spectrum Beta-Lactam Resistance (ESBL) 5906 510 46 64 20 11
ESBL Klebsiella 2763 192 11 13 10 8
ESBL Escherichia coli 3952 191 5 20 12 6
ESBL Acinetobacter 505 64 5 4 6 1
ESBL Pseudomonas 853 98 7 8 6 0
Carbapenems 17,031 1992 135 193 114 34
Carbapenem Resistance (CRE) 11,981 1461 118 164 95 20
CRE Enterobacteriaceae 2085 344 50 64 7 0
CRE Klebsiella 3067 292 22 42 19 4
CRE Acinetobacter 2959 334 36 32 23 3
CRE Pseudomonas 3142 377 28 36 22 5
Colistin 7027 653 72 78 21 4
Colistin resistance 4640 509 62 63 18 3
mcr colistin resistance 625 39 7 13 0 0
Colistin resistance, Enterobacter 1712 150 20 29 2 0
Colistin resistance, Klebsiella 914 111 12 13 3 0
Colistin resistance, Acinetobacter 1363 185 22 17 9 1
Colistin resistance, Pseudomonas 1123 154 10 14 11 2
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Table 1. Cont.
B. Temporal Distribution of PubMed Cited Reviews on Multidrug- Resistance (MDR), Extended Spectrum (XDR)
Resistance, and Pan-resistance in Clonal and Polyclonal Disseminating Gram-Negative ESKAPE Pathogens
Questions to PubMed (Entries)
Answers (Items): Articles: A, Reviews: R)
ALL 2019 2018 2009 2001
A R R R R R
Acinetobacter MDR 1261 174 25 25 10 0
Acinetobacter MDR/XDR 18 2 0 0 0 0
Acinetobacter Pandrug-resistant 96 23 2 4 2 0
Pseudomonas MDR 1310 165 19 27 9 2
Pseudomonas MDR/XDR 25 4 0 1 0 0
Pseudomonas Pandrug-resistant 52 1 1 2 1 0
Klebsiella MDR 1056 100 18 14 4 1
Klebsiella MDR/XDR 9 2 1 1 0 0
Klebsiella Pandrug-resistant 48 11 1 1 0 0
Enterobacter MDR 272 14 5 1 1 0
Enterobacter MDR/XDR 8 2 1 0 0 0
Enterobacter Pandrug-resistant 1 0 0 0 0 0
cephalosporin resistant Enterobacteriaceae MDR 121 12 2 3 0 0
cephalosporin resistant Enterobacteriaceae MDR/XDR 1 0 0 0 0 0
cephalosporin-resistant Enterobacteriaceae Pandrug-resistant 0 0 0 0 0 0
Salmonella typhi MDR 177 23 2 3 1 0
Salmonella typhi MDR/XDR 8 1 0 0 1 0
Salmonella typhi Pandrug-resistant 0 0 0 0 0 0
Escherichia coli MDR 1721 107 12 12 6 3
Escherichia coli MDR/XDR 8 1 0 0 0 0
Escherichia coli Pandrug-resistant 24 3 0 0 0 0
C. Temporal Distribution of PubMed Cited Reviews on Multidrug- Resistance (MDR), Extended Spectrum (XDR)
Resistance, and Pan-resistance in Bacteria Recently Scored to the Gram-Negative ESKAPE Pathogens [119]
Questions to PubMed (Entries)
Evoked Items: Articles: A, Reviews: R)
ALL 2019 2018 2009 2001
A R R R R R
Helicobacter pylori MDR 54 2 0 1 0 0
Helicobacter pylori MDR/XDR 0 0 0 0 0 0
Helicobacter pylori Pandrug-resistant 1 1 0 0 0 0
clarithromycin-resistant Helicobacter pylori 316 33 3 5 0 1
clarithromycin-resistant Helicobacter pylori MDR 4 0 0 0 0 0
clarithromycin-resistant Helicobacter pylori MDR/XDR 0 0 0 0 0 0
clarithromycin-resistant Helicobacter pylori Pandrug-resistant 0 0 0 0 0 0
Campylobacter MDR 72 5 0 1 1 0
Campylobacter MDR/XDR 0 0 0 0 0 0
Campylobacter Pandrug-resistant 0 0 0 0 0 0
fluoroquinolone-resistant Campylobacter 69 10 4 3 2 3
fluoroquinolone-resistant Campylobacter MDR 4 0 0 0 0 0
fluoroquinolone-resistant Campylobacter MDR/XDR 0 0 0 0 0 0
fluoroquinolone-resistant Campylobacter Pandrug-resistant 0 0 0 0 0 0
Neisseria gonorrhoeae MDR 44 3 0 0 0 0
Neisseria gonorrhoeae MDR/XDR 0 0 0 0 0 0
Neisseria gonorrhoeae Pandrug-resistant 0 0 0 0 0 0
Legend to Table 1: The number of publications on anti-Gram-negative compounds in beta-lactams is an order
of magnitude larger than those publications on carbapenem. The number of publications about CRE is about
a half order of magnitude larger than about ESBL and gradually increasing, especially in Enterobacteriaceae.
The majority of colistin resistance-related publications appeared in the last decade, but each resistance seems to be a
rather permanent, rather than alarming problem, if we consider the number of reviews as an indicator (Table 1A).
The publications found by entry on MDR are very high for each ESKAPE Gram-negative pathogen, with Escherichia
coli showing a significant but not sharp increase. However, MDR/XDR evoked a significant number of items, only on
the clonally distributing ESKAPE pathogens, and few of the others, including E. coli. The entry PDR evoked a
significant number of items, only on the clonally distributing ESKAPE pathogens, and few of the others, except
for E. coli with 24 items (Table 1B). As for the new “ESKAPE Club members”, only one publication reported PDR
(in Helicobacter), and none for XDR. However, the entry MDR invoked a significant number of recent publications
(Table 1C).
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Table 2. Temporal distribution of PubMed cited reviews on MDR-related issues in Gram-positive
ESKAPE bacteria.
Questions to PubMed (Entries) Evoked Items: Articles: A, Reviews: R)
ALL 2019 2018 2009 2001
A R R R R R
A. Temporal Distribution of PubMed Cited Reviews on MDR-related issues with MRSA Staphylococcus aureus
S. aureus MRSA 31,827 2098 141 249 384 161
S. aureus MRSA Antibiotic Resistance 15,822 2085 35 83 148 109
S. aureus Vancomycin Resistance 6448 1119 22 36 73 60
S. aureus MRSA VAN-R 4591 885 13 28 50 42
S. aureus Daptomycin resistance 1462 319 11 17 26 1
S. aureus MRSA DAP-R 1169 264 10 13 18 2
S. aureus Carbapenem Resistance 1189 187 16 19 9 3
Teixobactin 69 13 1 4 0 0
Teixobactin, MRSA 15 3 0 0 0 0
S. aureus MDR 1122 119 9 17 9 2
MDR/XDR Gram-positive 21 5 1 2 0 0
MDR/XDR S. aureus 3 2 1 1 0 0
B. Temporal Distribution of PubMed Cited Reviews on MDR-related Issues in the genus Enterococcus
Enterococcus Antibiotic Resistance 9167 1060 26 50 51 51
Enterococcus MDR 418 44 6 5 0 2
Enterococcus MDR/XDR 2 2 1 1 0 0
Enterococcus methicillin-resistant 2253 453 18 22 23 19
Enterococcus Vancomycin Resistance 5355 713 55 77 53 58
Enterococcus VRE 2247 274 10 20 6 14
E. faecium Vancomycin Resistance 2635 226 10 12 8 14
E. faecium VRE 985 83 5 6 2 7
E. faecalis Vancomycin Resistance 1824 241 6 11 6 4
E. faecalis VRE 564 45 1 4 1 3
E. caecum Vancomycin Resistance 13 0 0 0 0 0
E. gallinarum Vancomycin Resistance 278 10 11 2 6 7
Enterococcus Daptomycin resistance 584 120 30 42 35 7
E. faecium Daptomycin resistance 347 47 3 2 4 4
E. faecalis Daptomycin resistance 295 33 1 2 2 0
E. caecum Daptomycin Resistance 2 0 0 0 0 0
E. gallinarum Daptomycin Resistance 11 1 0 0 0 0
Enterococcus carbapenem resistance 524 72 7 5 2 2
C. Antibiotic Multiresistance (MDR), Extreme Large Spectrum (XDR) Resistance, and Pan-resistance in
Gram-Positive ESKAPE Pathogens
Gram-positive bacteria MDR 4292 542 11 42 34 12
Gram-positive bacteria MDR/XDR 21 5 1 2 0 0
Gram-positive bacteria PDR 17 6 0 1 0 0
S. aureus MDR 1122 119 9 17 9 2
S. aureus MDR/XDR 3 2 1 1 0 0
S. aureus Pandrug-resistant 19 9 0 2 0 0
S. aureus MRSA MDR 715 84 6 14 8 1
S. aureus MRSA MDR/XDR 2 2 1 3 0 0
S. aureus MRSA Pandrug-resistant 12 5 0 1 0 0
Enterococcus MDR 418 44 6 4 0 2
Enterococcus MDR/XDR Enterococcus 3 1 1 0 0 0
Enterococcus Pandrug-resistant 9 4 0 1 0 0
Enterococcus VRE MDR 92 12 3 4 0 0
Enterococcus VRE MDR/XDR 1 1 1 0 0 0
Enterococcus VRE Pandrug-resistant 3 0 0 0 0 0
Legend to Table 2: The bulk of the MRSA literature deals with antibiotic resistance. Interestingly, the temporal
distributions of VAN-R and DAP-R MRSA publications are almost even, indicating a serious and permanent, but not
an alarming, situation. A significant amount of the literature deals with carbapenem resistance in every year,
and surprisingly few are about teixobactin in MRSA, as if this antibiotic, which was discovered 4 years ago, would
not have been the dreamed for Jolly Joker antibiotic (Table 2A). Like polyclonally disseminating Gram-negative
ESKAPE pathogens, despite the large number (1122) of MDR-subjected publications, only 3 items were found
with MDR/XDR in a MRSA entry (Table 2C). The trend in Enterococci is rather similar. However, unlike the MRSA
literature, the number of MDR articles is dramatically increasing for the Enterococcus literature, especially E. faecium,
which seems to be in antibiotic-resistance evolutionary bloom. As far as we know, there is no known clonally
disseminating pan-genomic Gram-positive pathogen species, and few references about Gram-positive XDR isolates
were found, even though <5% of the publications about PDR isolates are cited by PubMed.
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Table 3 demonstrates that literature of the two pangenomic Gram-negatives is the largest, and many
of the publications deal with MDR, XDR, and PDR problems. The only significant difference between
the two species is that Pseudomonas has a large host range, including plants, while the host range
of Acinetobacter is extremely narrow. We did not focus on Klebsiella in this review. Very few of the
Acinetobacter and Pseudomonas publications deal with collateral sensitivity, and that is not good news.
It probably indicates that this evolutionary mechanism is not working in pangenomic bacteria. It should
urgently be experimentally tested.
Table 3. Temporal distribution of antibiotic resistance related PubMed cited reviews on genetics and
genomics of the open pan-genomic Gram-negative pathogens Acinetobacter baumannii and Pseudomonas
aeruginosa.
Questions to PubMed (Entries) Evoked Items: Articles: A, Reviews: R
ALL 2019 2018 2009 2001
A R R R R R
Acinetobacter
Intrinsic resistance 243 46 2 3 2 0
Acquired Resistance 1208 243 9 14 16 6
Resistance genes 1808 103 11 10 3 1
Plasmids, Genomic Islands 27 4 0 1 0 0
Antibiotic Resistance mechanisms 932 206 14 13 11 2
Antibiotic Resistance, Genome plasticity 24 4 0 0 0 0
Horizontal Gene Transfer 210 16 0 1 1 0
Pangenome pangenomic 9 1 0 0 0 0
Clonal Global Distribution 16 1 0 0 0 0
Diseases 4237 530 45 50 36 18
Host range 73 9 1 0 0 0
Collateral Sensitivity 5 1 0 0 0 0
Pseudomonas
Intrinsic resistance 577 117 8 11 3 4
Acquired Resistance 2249 437 25 32 27 12
Resistance genes 4647 233 12 17 4 6
Plasmids, Genomic Islands 39 2 0 0 0 0
Antibiotic Resistance mechanisms 2075 411 16 35 16 10
Resistance, Genome plasticity 36 4 1 0 0 0
Horizontal Gene transfer 512 44 2 3 2 1
Pangenome 50 4 0 0 0 0
Clonal Global Distribution 6 0 0 0 0 0
Diseases 22.950 2628 92 157 129 04
Host range 404 48 2 8 4 1
Collateral Sensitivity 10 1 0 0 0 0
8.3. Pharmaceutical Perspectives
8.3.1. Search for Omnipotent (“Jolly Joker”) Antibiotics
We feel the clinching argument for our view of science is as follows. So far, science has produced
“cards”, including the ace cards” (colistin, daptomycin) for the “card games”, but each was “hit” by
the respective resistances. “Jolly Jokers” are needed. One “Jolly Joker” (teixobactin) [383] active in
Gram-positive bacteria has been identified. So far, no resistance has been noted [388].
8.3.2. The Perspectives of Antimicrobial Peptide (AMP) Molecules
The different types of multidrug resistances (MDR, XDR, PDR) are an enormous challenge with
clinical, veterinary, and plant-pathogenic significance. This review aimed to give a general view rather
than specific perspectives. We are aware that chemotherapeutic tools should always be available,
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ready to combat new pathogens and overcome any new resistance. We are convinced that due to their
molecular heterogeneity, structural versatility, and target spectra, the natural antimicrobial peptide
(AMP) molecules and synthetic derivatives provide an inexhaustible source of new optimized toolkits
capable of combatting new MDR pathogens. Furthermore (as discussed in 6.4.1), both the mobilization
patterns, as well as the functional compatibilities with new target bacterial hosts of AMP-resistance
genes, and traditional antibiotic-resistance genes, are different.
The AMP research strategy relies on searching for new natural molecules, computer-design and
quantitative structure–activity relationships (QSAR), and analysis of derivatives to provide databases
for getting descriptor molecules with better pharmacokinetic profiles. Many natural AMPs are primary
(ribosome-templated) gene products. Others are or non-ribosomal-templated peptide (NRP) molecules,
synthesized enzymatically by multienzyme thiotemplate mechanisms using non-ribosomal peptide
synthetases (NRPS) and/or fatty acid synthase (FAS)-related polyketide synthases. Our next review
(Fodor et al., in preparation) will provide a useable inventory of AMPs. This includes primary
gene products (from mammals, free-living bacteria, plants, plant-bacterium symbiotic associations,
and insects) and NRPs. In that review, we intend to discuss the role of natural AMPs in plant innate
immune defense mechanisms, especially genetic aspects discovered in Arabidopsis thaliana.
The specificity of the resistance mechanism is based on Microbe-Associated Molecular
Patterns (MAMPs). The anti-MDR potential of the large target-spectral NRP-AMPs produced by
obligate bacterial symbiotic bacteria (EPB, belonging to the genera Xenorhabdus, Photorhabdus) of
entomopathogenic nematodes (EPN, Steinernema, Heterorhabditis species) in vitro is excellent. Their
natural role is to provide monoxenic conditions for the respective EPN/EPB symbiotic “couple” in
polyxenic (soil, cadaver) environments. They are effective against a large number of both prokaryotic
and eukaryotic opportunistic soil microbes, as well as against human, veterinary, and plant-pathogen
organisms which they have never encountered in nature (as noted in several labs). They might
successfully be applied more efficiently for plant protection as soil ingredients than in clinical practice.
As discussed in Sections 4.2.6, 4.2.7 and 5.1, some NPR-AMPs (vancomycin, daptomycin,
teixobactin) were efficient against Gram-positive targets. All but teixobactin has been overcome
by resistance. Others (colistin, Sections 3.6 and 3.7) were used against Gram-negative MDR targets,
but have also been overcome by resistance. Some drug candidates with unnatural (beta) amino acid
substituents are extremely efficient against ESKAPE pathogens [383,391]. Others (ARV-1502) are in
clinical studies [402,403].
As discussed in Section 5.2, the proline-rich AMPs (PrAMPs of insect origin and their optimized
derivatives) are of a uniquely outstanding medical perspective, especially because they have a larger
target spectrum in vivo than in vitro. These data confirm our previous conclusion that the battle
between newly appearing representatives of MDR and novel AMPs is permanent and endless.
We note the availability of recently available AMP databases that could be used for modeling.
The best ones are as follows: DBAASP (PubMed: 27060142), APD3 (PubMed: 26602694),
CAMP (PubMed: 19923233), LAMP (PubMed: 23825543), and dbAMP (PubMed: 30380085), just to
mention a few. In addition, Spanig and Heider recently published a review on AMP modeling for
diagnostics (PubMed: 30867681), which we referred to as [391].
8.4. Closing Remark
Apart from natural reasons (phylogenetic barriers, collateral sensitivity), the profession ability of
molecular designers and the availability of abundant natural sources of antimicrobial peptides with
structural diversity and heterogeneity can assure the post-antibiotic age will never come. The question
is whether nature will, or will not, be able to invent new wedges (resistance) against the new potential
“Jolly Jokers” (AMPs).
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